IRVINE, California - Edwards Lifesciences (NYSE:EW) has received U.S. Food and Drug Administration approval for its SAPIEN M3 mitral valve replacement system, marking the first transcatheter therapy ...

Investing.com -- Edwards Lifesciences has received FDA approval for its SAPIEN M3 mitral valve replacement system, marking a significant advancement in heart valve treatment options. The SAPIEN M3 is ...

Please provide your email address to receive an email when new articles are posted on . A transseptal mitral valve replacement system was approved for patients unsuitable for surgery or transcatheter ...

Edwards Lifesciences’ SAPIEN M3 mitral valve replacement system has become the first transcatheter therapy utilizing a transseptal approach to snag FDA approval in the U.S. for the treatment of mitral ...

IRVINE, Calif., December 23, 2025--(BUSINESS WIRE)--Edwards Lifesciences (NYSE: EW) today announced the company’s SAPIEN M3 mitral valve replacement system is the first transcatheter therapy utilizing ...

Edwards has received Food and Drug Administration approval for its Sapien M3 mitral valve replacement system, the company said Tuesday. The device is intended for people with moderate to severe mitral ...

A NEW analysis reveals that transcatheter mitral valve replacement delivers sustained benefits for patients with high-risk mitral regurgitation, demonstrating long term stability and improved symptoms ...

QUEBEC CITY — Although women appear to benefit as much as men do from left atrial appendage occlusion (LAAO) during surgery for atrial fibrillation (AF), they have far worse 30-day outcomes following ...

Background Mitral valve prolapse (MVP) can be associated with ventricular arrhythmias (VA), but little is known about the relationship between VA and exercise in these patients. The aim of this study ...